Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 5

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 5
---
 of securities offered hereby may be effected in one or more transactions that may take place in ordinary brokers’
transactions, privately negotiated transactions or through sales to one or more dealers for resale of such securities as principals.
Usual and customary or specifically negotiated brokerage fees or commissions may be paid by the Selling Stockholders. The sale of the
Shares by Selling Stockholders in the Resale Offering is not conditioned upon the successful completion of the sale of the Units by the
Company in the Primary Offering. The fixed price that the Selling Stockholders can sell their Shares may be less than the price
an investor will pay for the Common Stock in the Primary Offering.

There may be substantial sales of our Common
Stock by the Selling Stockholders after the effective date of this registration statement which could have a material adverse effect
on the price of our Common Stock. See “Substantial future sales or perceived potential sales of Common Stock in the public market could cause the price of the Common Stock to decline” and “There may be substantial sales of our Common Stock by the Selling Stockholders after the effective date of this registration statement of which this prospectus forms a part, which could have a material adverse effect on the price of our Common Stock after the Primary Offering”.

On August 12, 2025, the last reported sale
price for our Common Stock on the OTC Market was $0.52 per share. The Selling Stockholders and any broker-dealers or agents that are
involved in selling the Shares may be deemed to be underwriters within the meaning of the Securities Act in connection with such sales.
In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the Shares purchased by them
may be deemed to be underwriting commissions or discounts under the Securities Act. See“Determination of the Offering Price,” “Selling Stockholders”and “Plan of Distribution.”

The Selling Stockholders will pay all underwriting
discounts and selling commissions relating to the sale of these shares. We have agreed to pay the legal, accounting, printing, and other
expenses related to the registration of the sale of the Shares of Common Stock in this Offering. All of the net proceeds from the sale
of the Shares in the Resale Offering by the Selling Stockholder will go to the Selling Stockholders. However, to the extent that the
Investor Warrants held by the Selling Stockholders are exercised for cash, we will receive payment of the exercise price in connection
with such exercise.

Investing in